Back to News
Press Release November 21, 2019

NEWS & EVENTS

News Image

Paris (France). November 21. 2019.Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial.

Read full article – PDF


Read full article